University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Dimethylvinyl chloride (CAS 513-37-1)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
eso nas orc ski sto eso nas orc sto pre sto sto 31.8m 14.9m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   eso = esophagus. nas = nasal cavity (includes tissues of the nose, nasal turbinates, paranasal sinuses and trachea). orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). pre = preputial gland. ski = skin. sto = stomach. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Dimethylvinyl chloride: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page. 



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code


DIMETHYLVINYL CHLORIDE   513-37-1
2376 M f b6c gav 24m24 TR316 :                       0    71.4mg  142.mg
 for MXA        14.3mg \ P<.0005 c  8.29mg 24.3mg   0/50   41/50  (36/50)                                         for:adq,can,sqc.
 for MXA        14.3mg \ P<.0005 c  8.29mg 24.3mg   0/50   41/50  (38/50)                                     for:adq,can,sqc,sqp.
 for sqc        14.4mg \ P<.0005 c  8.34mg 24.8mg   0/50   40/50  (36/50)
 for MXA        14.4mg \ P<.0005 c  8.34mg 24.8mg   0/50   40/50  (38/50)                                             for:sqc,sqp.
 MXA MXA        124.mg / P<.004     45.7mg 1.32gm  10/50    2/50   10/50               jej:mlp; liv:mlm; mul:mlh,mlm,mlp; spl:mlm. S
 hag ppa        146.mg * P<.0005    52.9mg 489.mg   0/50    3/50    5/50                                                           S
 liv hpa        150.mg * P<.007     50.0mg 3.68gm   4/50    4/50    4/50                                                           S
 lun MXA        186.mg * P<.003     58.7mg 1.62gm   3/50    1/50    7/50                                              lun:a/a,a/c. S
 lun a/a        235.mg * P<.004     68.5mg 2.72gm   2/50    1/50    6/50                                                           S
 for sqp        373.mg * P<.005  c  83.4mg 5.10gm   0/50    1/50    3/50
 MXA mlm        229.mg * P<.04      64.1mg n.s.s.   6/50    1/50    5/50                                liv:mlm; mul:mlm; spl:mlm. S
 TBA MXB        14.6mg * P<.0005    9.20mg 25.3mg  32/50   45/50   43/50
 liv MXB        150.mg * P<.007     50.0mg 3.68gm   4/50    4/50    4/50                                          liv:hpa,hpc,nnd.
 lun MXB        186.mg * P<.003     58.7mg 1.62gm   3/50    1/50    7/50                                              lun:a/a,a/c.
2377 M m b6c gav 24m24 TR316 :                       0    71.4mg  142.mg
 MXB MXB        15.2mg * P<.0005    9.93mg 23.6mg   2/50   44/50   42/50                                     for:sqc,sqp; pre:sqc. C
 for MXA        15.5mg * P<.0005 c  10.1mg 23.7mg   1/50   43/50   41/50                                              for:sqc,sqp.
 for sqc        17.2mg * P<.0005 c  11.2mg 26.2mg   0/50   42/50   35/50
 liv MXA        48.8mg * P<.0005    24.0mg 133.mg  11/50   12/50   13/50                                              liv:hpa,hpc. S
 liv hpa        87.1mg * P<.0005    36.4mg 407.mg   8/50    7/50    8/50                                                           S
 lun MXA        87.7mg * P<.0005    37.2mg 355.mg   6/50    9/50    8/50                                              lun:a/a,a/c. S
 pre sqc        90.7mg / P<.0005 c  41.8mg 213.mg   1/50    3/50   16/50
 liv hpc        104.mg * P<.0005    44.3mg 375.mg   3/50    6/50    7/50                                                           S
 lun a/a        117.mg * P<.002     43.2mg 778.mg   3/50    6/50    4/50                                                           S
 MXA MXA        148.mg * P<.008     51.1mg 4.32gm   6/50    6/50    6/50       duo:mlm; lyd:mno; mul:grl,mlh,mlm,mlp,mlu; spl:mlm. S
 hag ppa        149.mg * P<.004     50.4mg 1.51gm   2/50    3/50    3/50                                                           S
 MXA MXA        154.mg * P<.009     52.0mg 7.57gm   6/50    5/50    6/50           duo:mlm; lyd:mno; mul:mlh,mlm,mlp,mlu; spl:mlm. S
 for sqp        195.mg * P<.0005 c  66.8mg 827.mg   1/50    3/50    8/50
 lun a/c        199.mg * P<.007     65.5mg 3.88gm   3/50    4/50    5/50                                                           S
 MXA MXA        221.mg * P<.008     68.2mg 5.79gm   2/50    3/50    4/50                   liv:hem,hes; mln:hem; pre:hem; spl:hes. S
 MXA hes        375.mg * P<.03      83.9mg n.s.s.   1/50    1/50    3/50                                         liv:hes; spl:hes. S
 TBA MXB        13.9mg * P<.0005    8.92mg 23.2mg  26/50   47/50   44/50
 liv MXB        48.8mg * P<.0005    24.0mg 133.mg  11/50   12/50   13/50                                          liv:hpa,hpc,nnd.
 lun MXB        87.7mg * P<.0005    37.2mg 355.mg   6/50    9/50    8/50                                              lun:a/a,a/c.
2378 R f f34 gav 23m24 TR316 :                       0    70.7mg  143.mg
 MXB MXB a      25.3mg / P<.0005    15.9mg 40.5mg   1/50   25/50   36/50  eso:sqc; for:sqc,sqp; gnv:sqc; nas:adc,adn,can,sqc; orm:
                                                                                                        sqp; pal:sqc,sqp; ton:sqc. C
 nas MXA a      34.3mg / P<.0005 c  20.8mg 55.6mg   0/50   17/50   35/50                                      nas:adc,adn,can,sqc.
 nas MXA a      35.2mg / P<.0005 c  21.1mg 57.5mg   0/50   16/50   35/50                                          nas:adc,can,sqc.
 mgl MXA a      36.7mg / P<.0005    19.1mg 89.9mg  11/50   21/50    5/50                                              mgl:adc,fba. S
 mgl fba a      38.3mg / P<.0005    19.5mg 98.1mg  10/50   18/50    5/50                                                           S
 nas MXA a      46.8mg / P<.0005 c  26.9mg 77.7mg   0/50   13/50   29/50                                              nas:can,sqc.
 nas can a      52.7mg / P<.0005 c  29.2mg 89.1mg   0/50   11/50   28/50
 pta MXA a      68.0mg * P<.004     29.5mg 616.mg  17/50   17/50    2/50                                          pta:adn,cra,crc. S
 pta MXA a      71.7mg * P<.006     30.3mg 940.mg  17/50   16/50    2/50                                              pta:cra,crc. S
 ute MXA a      84.9mg * P<.002     35.3mg 543.mg   8/50   12/50    2/50                                              ute:esp,ess. S
 ute esp a      91.9mg * P<.004     36.6mg 801.mg   8/50   11/50    2/50                                                           S
 for MXA a      95.2mg * P<.0005 c  40.2mg 313.mg   1/50    9/50    2/50                                              for:sqc,sqp.
 thy MXA a      131.mg * P<.002     44.3mg 994.mg   1/50    5/50    1/50                                              thy:fca,fcc. S
 thy fcc a      136.mg * P<.004     44.9mg 1.53gm   1/50    5/50    0/50                                                           S
 nas MXA a      143.mg / P<.0005 c  54.6mg 412.mg   0/50    4/50    6/50                                              nas:adc,adn.
 nas adc a      159.mg / P<.0005 c  56.8mg 504.mg   0/50    3/50    6/50
 for sqc a      191.mg * P<.0005 c  65.9mg 832.mg   0/50    5/50    1/50
 for sqp a      209.mg * P<.008  c  62.0mg 7.92gm   1/50    4/50    1/50
 lun MXA a      218.mg * P<.002     70.5mg 1.11gm   0/50    4/50    1/50                                              lun:a/a,a/c. S
 eso sqc a      250.mg * P<.003  c  72.5mg 1.89gm   0/50    3/50    1/50
 MXA MXA a      318.mg / P<.0005 c  117.mg 1.13gm   0/50    2/50    5/50                   gnv:sqc; orm:sqp; pal:sqc,sqp; ton:sqc.
 MXA sqp a      1.01gm / P<.006  c  343.mg 10.5gm   0/50    0/50    4/50                                         orm:sqp; pal:sqp.
 pta MXA a      101.mg * P<.03      37.4mg n.s.s.  16/50   13/50    2/50                                              pta:adn,cra. S
 pta cra a      109.mg * P<.04      38.9mg n.s.s.  16/50   12/50    2/50                                                           S
 mul MXA a      170.mg * P<.02      59.6mg n.s.s.   5/50    8/50    1/50                                              mul:lle,mnl. S
 mul mnl a      202.mg * P<.04      64.5mg n.s.s.   5/50    7/50    1/50                                                           S
 pta crc a      222.mg * P<.02      64.6mg n.s.s.   1/50    4/50    0/50                                                           S
 thy cca a      225.mg * P<.04      64.4mg n.s.s.   3/50    4/50    1/50                                                           S
 orm sqp a      1.22gm / P<.02   c  369.mg n.s.s.   0/50    0/50    3/50
 TBA MXB a      11.9mg / P<.0005    7.69mg 19.4mg  33/50   48/50   42/50
 liv MXB a      no dre   P=1.       n.s.s. n.s.s.   0/50    0/50    0/50                                          liv:hpa,hpc,nnd.
2379 R m f34 gav 22m24 TR316 :                       0    70.7mg  143.mg
 tes ict a      13.9mg / P<.0005    7.93mg 30.9mg  40/50   41/50    6/50                                                           S
 MXB MXB a      17.5mg / P<.0005    10.8mg 28.5mg   0/50   33/50   29/50  eso:sqc,sqp; for:sqc,sqp; lpp:sqc; nas:adc,can,sqc; pal:
                                                                                                             sqc,sqp; ton:sqc,sqp. C
 nas MXA a      29.7mg / P<.0005 c  18.2mg 47.1mg   0/50   23/50   28/50                                          nas:adc,can,sqc.
 for MXA a      41.6mg * P<.0005 c  19.8mg 98.0mg   0/50   14/50    0/50                                              for:sqc,sqp.
 nas MXA a      52.1mg / P<.0005 c  32.0mg 84.8mg   0/50   15/50   24/50                                              nas:can,sqc.
 nas can a      63.4mg / P<.0005 c  38.2mg 101.mg   0/50   12/50   24/50
 for sqp a      67.1mg * P<.0005 c  26.7mg 230.mg   0/50    7/50    0/50
 nas acn a      70.1mg / P<.0005    29.7mg 185.mg   0/50    8/50    4/50                                                           S
 eso MXA a      81.6mg / P<.0005 c  32.0mg 249.mg   0/50    6/50    4/50                                              eso:sqc,sqp.
 mul mnl a      128.mg * P<.006     44.2mg 2.22gm   3/50    6/50    1/50                                                           S
 for sqc a      135.mg * P<.0005 c  50.3mg 463.mg   0/50    7/50    0/50
 eso sqc a      143.mg * P<.0005 c  44.3mg 770.mg   0/50    4/50    1/50
 MXA MXA a      163.mg * P<.0005 c  56.5mg 511.mg   0/50    5/50    4/50                        lpp:sqc; pal:sqc,sqp; ton:sqc,sqp.
 MXA sqc a      178.mg * P<.0005 c  58.0mg 708.mg   0/50    5/50    2/50                                lpp:sqc; pal:sqc; ton:sqc.
 eso sqp a      218.mg * P<.002  c  59.8mg 1.31gm   0/50    2/50    3/50
 nas sqc a      297.mg * P<.009  c  87.7mg 13.1gm   0/50    3/50    0/50
 ton MXA a      415.mg * P<.002  c  157.mg 2.06gm   0/50    3/50    3/50                                              ton:sqc,sqp.
 ton sqc a      469.mg * P<.005  c  165.mg 4.25gm   0/50    3/50    2/50
 MXA MXA a      86.7mg / P<.02      29.2mg n.s.s.  13/50    7/50    3/50                                         adr:phm; amd:phe. S
 TBA MXB a      10.2mg / P<.0005    6.56mg 17.2mg  40/50   48/50   37/50
 liv MXB a      1.03gm / P<.3       107.mg n.s.s.   1/50    0/50    1/50                                          liv:hpa,hpc,nnd.
Mutagenicity in Salmonella: positive
SMILES Code for Dimethylvinyl chloride: CC(=CCl)C
InChI Code for Dimethylvinyl chloride: InChI=1/C4H7Cl/c1-4(2)3-5/h3H,1-2H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Dimethylvinyl chloride: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (support@leadscope.com).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10